SB
VRTX icon

Strategic Blueprint’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Blueprint’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$322K Buy
721
+121
+20% +$56.4K 0.02% 504
2025
Q4 		$272K Sell
600
-1,164
-66% -$502K 0.02% 544
2025
Q3 		$691K Sell
1,764
-43
-2% -$18K 0.03% 412
2025
Q2 		$804K Buy
1,807
+309
+21% +$142K 0.04% 345
2025
Q1 		$726K Buy
1,498
+25
+2% +$11.7K 0.04% 345
2024
Q4 		$593K Buy
1,473
+386
+36% +$179K 0.04% 372
2024
Q3 		$506K Buy
1,087
+7
+0.6% +$3.36K 0.03% 396
2024
Q2 		$506K Buy
1,080
+120
+13% +$52.1K 0.03% 377
2024
Q1 		$401K Buy
960
+304
+46% +$129K 0.03% 427
2023
Q4 		$267K Buy
+656
New +$242K 0.02% 486
2021
Q3 		– Sell
-59
Closed -$12K – 1305
2021
Q2 		$12K Buy
+59
New +$12.3K ﹤0.01% 937
2020
Q4 		– Sell
-1,278
Closed -$348K – 265
2020
Q3 		$348K Buy
+1,278
New +$353K 0.11% 155

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Strategic Blueprint's VRTX Position: Q1 2026 in Review

Strategic Blueprint increased its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, buying an estimated $56.4K and bringing the position to 721 shares worth $322K. The position accounts for 0.02% of the portfolio, ranked #504.

Strategic Blueprint first reported a position in VRTX in Q3 2020 and has held it in 12 quarters since. The position peaked at $804K in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Strategic Blueprint held 721 shares of Vertex Pharmaceuticals worth $322K as of Q1 2026.
  • Strategic Blueprint bought 121 Vertex Pharmaceuticals shares in Q1 2026, an estimated $56.4K.
  • Vertex Pharmaceuticals made up 0.02% of Strategic Blueprint's portfolio in Q1 2026, its #504 holding.
  • Strategic Blueprint first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 12 quarters since.
  • Strategic Blueprint's Vertex Pharmaceuticals position peaked at $804K in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Strategic Blueprint's 13F filing for Q1 2026, filed 29 Apr 2026.